New findings in preventing recurrence and improving renal function in AHUS patients after renal transplantation treated with eculizumab: a systemic review and meta-analyses

References

• Yan K, Desai K, Gullapalli L, et al. Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review. Clin Epidemiol. 2020;12:1–12. doi:10.2147/CLEP.S245642.
   PubMed Web of Science ®Google Scholar
• Ariceta G, Dixon BP, Kim SH, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int. 2021;100(1):225–237. doi:10.1016/j.kint.2020.10.046.
   PubMed Web of Science ®Google Scholar
• Ariceta G, Besbas N, Johnson S, et al. Guideline for the investigation and initial therapy of diarrhea negative hemolytic uremic syndrome. Pediatr Nephrol. 2009;24(4):687–696. doi:10.1007/s00467-008-0964-1.
   PubMed Web of Science ®Google Scholar
• Taylor CM, Machin S, Wigmore SJ, et al. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol. 2010;148(1):37–47. doi:10.1111/j.1365-2141.2009.07916.x.
   PubMed Web of Science ®Google Scholar
• Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2008;23(11):1957–1972. doi:10.1007/s00467-008-0872-4.
   PubMed Web of Science ®Google Scholar
• Barz D, Budde U, Hellstern P. Therapeutic plasma exchange and plasma infusion in thrombotic microvascular syndromes. Thromb Res. 2002;107(Suppl 1):S23–S27. doi:10.1016/S0049-3848(02)00148-2.
   PubMedGoogle Scholar
• von Baeyer H. Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Therapher Dial. 2002;6(4):320–328. doi:10.1046/j.1526-0968.2002.00390.x.
   Google Scholar
• Waters AM, Licht C. AHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol. 2011;26(1):41–57. doi:10.1007/s00467-010-1556-4. Epub 2010 Jun 18. Erratum in: Pediatr Nephrol. 2013 Jan;28(1):165.
   PubMed Web of Science ®Google Scholar
• Bresin E, Daina E, Noris M, et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol. 2006;1(1):88–99. doi:10.2215/CJN.00050505.
   PubMed Web of Science ®Google Scholar
• Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet. 2005;14(5):703–712. doi:10.1093/hmg/ddi066.
   PubMed Web of Science ®Google Scholar
• Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267–1279. doi:10.1182/blood-2005-10-007252.
   PubMed Web of Science ®Google Scholar
• Sheerin NS, Kavanagh D, Goodship TH, et al. A national specialized service in England for atypical haemolytic uraemic syndrome-the first year’s experience. QJM. 2016;109(1):27–33. doi:10.1093/qjmed/hcv082.
   PubMed Web of Science ®Google Scholar
• Krishnappa V, Gupta M, Elrifai M, et al. Atypical hemolytic uremic syndrome: a meta-analysis of case reports confirms the prevalence of genetic mutations and the shift of treatment regimens. Ther Apher Dial. 2018;22(2):178–188. doi:10.1111/1744-9987.12641.
   PubMed Web of Science ®Google Scholar
• Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169–2181. doi:10.1056/NEJMoa1208981.
   PubMed Web of Science ®Google Scholar
• Goodship TH, Cook HT, Fakhouri F, et al. Atypical ­hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “kidney disease: improving global outcomes” (KDIGO) controversies conference. Kidney Int. 2017;91(3):539–551. doi:10.1016/j.kint.2016.10.005.
   PubMed Web of Science ®Google Scholar
• Wijnsma KL, Duineveld C, Wetzels JFM, et al. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol. 2019;34(11):2261–2277. doi:10.1007/s00467-018-4091-3. Epub 2018 Nov 6. Erratum in: Pediatr Nephrol. 2019 Jan 15;
   PubMed Web of Science ®Google Scholar
• Brodsky RA. Eculizumab and AHUS: to stop or not. Blood. 2021;137(18):2419–2420. doi:10.1182/blood.2020010234. PMID: 33956069; PMCID: PMC8109016.
   PubMed Web of Science ®Google Scholar
• Gonzalez Suarez ML, Thongprayoon C, Mao MA, et al. Outcomes of kidney transplant patients with atypical hemolytic uremic syndrome treated with eculizumab: a systematic review and meta-analysis. JCM. 2019;8(7):919. doi:10.3390/jcm8070919.
   Google Scholar
• Higgins, J.P.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. BMJ, 7414 2003,327, 557–560 doi:10.1136/bmj.327.7414.557.
   PubMed Web of Science ®Google Scholar
• Easterbrook PJ, Berlin JA, Gopalan R, et al. Publication bias in clinical research. Lancet. 1991;337(8746):867–872. doi:10.1016/0140-6736(91)90201-y.
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in metaanalyses. Eur J Epidemiol. 2010;25(9):603–605. doi:10.1007/s10654-010-9491-z.
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in metaanalyses [EB/OL]. Ottawa: OHRI; 2012.
   Google Scholar
• Munn Z, Barker TH, Moola S, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synthesis. 2020;18(10):2127–2133.
   PubMedGoogle Scholar
• Sprenkle P, Russo P. Molecular markers for ischemia, do we have something better than creatinine and glomerular filtration rate? Arch Esp Urol. 2013;66(1):99–114.
   PubMed Web of Science ®Google Scholar
• Levey AS, Gansevoort RT, Coresh J, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the national kidney foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020;75(1):84–104. doi:10.1053/j.ajkd.2019.06.009.
   PubMed Web of Science ®Google Scholar
• Cavero T, Rabasco C, López A, et al. Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol Dial Transplant. 2017;32(3):466–474. doi:10.1093/ndt/gfw453.
   PubMed Web of Science ®Google Scholar
• Palma LMP, Eick RG, Dantas GC, et al. Atypical hemolytic uremic syndrome in Brazil: clinical presentation, genetic findings and outcomes of a case series in adults and children treated with eculizumab. Clin Kidney J. 2021;14(4):1126–1135. doi:10.1093/ckj/sfaa062.
   PubMed Web of Science ®Google Scholar
• Kant S, Bhalla A, Alasfar S, et al. Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome– a single center experience. BMC Nephrol. 2020;21(1):189. doi:10.1186/s12882-020-01847-0.
   PubMed Web of Science ®Google Scholar
• de Andrade LGM, Contti MM, Nga HS, et al. Long-term outcomes of the Atypical Hemolytic Uremic Syndrome after kidney transplantation treated with eculizumab as first choice. PLoS One. 2017;12(11):e0188155. doi:10.1371/journal.pone.0188155
   PubMed Web of Science ®Google Scholar
• Levi C, Frémeaux-Bacchi V, Zuber J, et al. Midterm outcomes of 12 renal transplant recipients treated with eculizumab to prevent atypical hemolytic syndrome recurrence. Transplantation. 2017;101(12):2924–2930. doi:10.1097/TP.0000000000001909.
   PubMed Web of Science ®Google Scholar
• Baskin E, Fidan K, Gulhan B, et al. Eculizumab treatment and discontinuation in pediatric patients with atypical hemolytic uremic syndrome: a multicentric retrospective study. J Nephrol. 2022;35(4):1213–1222. doi:10.1007/s40620-021-01212-w.
   PubMed Web of Science ®Google Scholar
• Siedlecki AM, Isbel N, Vande Walle J, et al. Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome. Kidney Int Rep. 2019;4(3):434–446. doi:10.1016/j.ekir.2018.11.010.
   PubMed Web of Science ®Google Scholar
• Ariceta G, Fakhouri F, Sartz L, et al. Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes. Clin Kidney J. 2021;14(9):2075–2084. Jan 24 doi: 10.1093/ckj/sfab005. PMID: 35261761;
   PubMed Web of Science ®Google Scholar
• Nga HS, Palma LMP, Ernandes Neto M, et al. Thrombotic microangiopathy after kidney transplantation: analysis of the Brazilian atypical hemolytic uremic syndrome cohort. PLoS One. 2021;16(11):e0258319. pone.0258319 doi:10.1371/journal.
   PubMed Web of Science ®Google Scholar
• Mallett A, Hughes P, Szer J, et al. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort. Intern Med J. 2015;45(10):1054–1065. doi:10.1111/imj.12864.
   PubMed Web of Science ®Google Scholar
• Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial AHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844–1859. doi:10.2215/CJN.02210310. Epub 2010 Jul 1. PMID: 20595690; PMCID: PMC2974386.
   PubMed Web of Science ®Google Scholar
• Noris M, Bresin E, Mele C, et al. Genetic atypical hemolytic-uremic syndrome. In: Adam MP, Everman DB, Mirza GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews^®. Seattle (WA): University of Washington, Seattle; 2007. p. 1993–2022. PMID: 20301541.
   Google Scholar
• Matar D, Naqvi F, Racusen LC, et al. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation. 2014;98(11):1205–1212. doi:10.1097/TP.0000000000000200. PMID: 24933457.
   PubMed Web of Science ®Google Scholar
• Ardissino G, Cresseri D, Tel F, et al. Kidney transplant in patients with atypical hemolytic uremic syndrome in the anti-C5 era: single-center experience with tailored eculizumab. J Nephrol. 2021;34(6):2027–2036. doi:10.1007/s40620-021-01045-7.
   PubMed Web of Science ®Google Scholar
• Abazi-Emini N, Sahpazova E, Putnik J, et al. Anti-factor H antibody-associated atypical hemolytic uremic syndrome: a case report. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2021;42(2):109–115. doi:10.2478/prilozi-2021-0029. PMID: 34699711.
   PubMedGoogle Scholar
• Boyer O, Balzamo E, Charbit M, et al. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies. Am J Kidney Dis. 2010;55(5):923–927. doi:10.1053/j.ajkd.2009.12.026.
   PubMed Web of Science ®Google Scholar
• Sana G, Dragon-Durey MA, Charbit M, et al. Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol. 2014;29(1):75–83. doi:10.1007/s00467-013-2558-9.
   PubMed Web of Science ®Google Scholar
• Glover EK, Smith-Jackson K, Brocklebank V, et al. Assessing the impact of prophylactic eculizumab on renal graft survival in atypical hemolytic uremic syndrome. Transplantation. 2023;107(4):994–1003. doi:10.1097/TP.0000000000004355.
   PubMed Web of Science ®Google Scholar
• Gema Ariceta Iraola M, Al-Dakkak I, Anokhina K, et al. FC 115: long-term outcomes in Eculizumab-Treated kidney transplant patients enrolled in the global atypical haemolytic uraemic syndrome registry. Nephrol Dial Transpl. 2022;37(Supplement_3). doi:10.1093/ndt/gfac123.004.
   Google Scholar
• Portoles J, Huerta A, Arjona E, et al. Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study. Clin Kidney J. 2021;14(4):1173–1180. doi:10.1093/ckj/sfaa096. PMID: 33841863; PMCID: PMC8023214.
   PubMed Web of Science ®Google Scholar
• Duineveld C, Bouwmeester R, van der Heijden JW, et al. Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal. Clin Kidney J. 2021;14(8):1939–1945. doi:10.1093/ckj/sfaa241.
   PubMed Web of Science ®Google Scholar
• González CC, López-Jiménez V, Vázquez-Sánchez T, et al. Efficacy and safety of eculizumab in kidney transplant patients with primary atypical hemolytic-uremic syndrome. Transplant Proc. 2022;54(1):25–26. doi:10.1016/j.transproceed.2021.09.063.
   PubMed Web of Science ®Google Scholar
• Alpay N, Ozçelik U. Renal transplantation in patients with atypical hemolytic uremic syndrome: a single center experience. Transplant Proc. 2019;51(7):2295–2297. doi:10.1016/j.transproceed.2019.01.157.
   PubMed Web of Science ®Google Scholar
• Duineveld C, Verhave JC, Berger SP, et al. Living donor kidney transplantation in atypical hemolytic uremic syndrome: a case series. Am J Kidney Dis. 2017;70(6):770–777. doi:10.1053/j.ajkd.2017.06.024. Epub 2017 Aug 16. PMID: 28821363.
   PubMed Web of Science ®Google Scholar
• Milan Manani S, Virzì GM, Giuliani A, et al. Hemolytic uremic syndrome and kidney transplantation: a case series and review of the literature. Nephron. 2017;136(3):245–253. doi:10.1159/000468528.
   PubMed Web of Science ®Google Scholar
• Legendre CM, Campistol JM, Feldkamp T, et al. Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis. Transpl Int. 2017;30(12):1275–1283. doi:10.1111/tri.13022.
   PubMed Web of Science ®Google Scholar
• Zuber J, Le Quintrec M, Krid S, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant. 2012;12(12):3337–3354. doi:10.1111/j.1600-6143.2012.04252.x.
   PubMed Web of Science ®Google Scholar